PharmaCyte Biotech Inc (PMCB)

[thenewmixer]

here another

SILVER SPRING, MD, September 18, 2014 (GLOBE NEWSWIRE)
The initial preclinical study being conducted by TD2 concerns the effectiveness of Nuvilex’s treatment in
slowing the accumulation of ascites fluid. For this work, a mouse model system is being used. Here, mice
are implanted with a type of human ovarian cancer cells that grow rapidly and produce significant amounts
of ascites fluid relatively quickly. The mice are then given pin-head-sized Cell-in-a-Box® capsules that
contain live cells capable of converting ifosfamide into its cancer-killing form. Finally, low doses
(compared to normal) of ifosfamide are administered. This study is currently underway. The results from
TD2’s work should be available relatively soon.
WHAT DOES SOON MEANone year two years never not really sure